Heart Failure Market 2025 Epidemiology Forecasts and Trends for US, France, Germany, Italy, Spain, UK and Japan
PUNE, India, June 6, 2016 /PRNewswire/ --
The heart failure market (HF) EpiCast report provides an overview of the risk factors and global trends of HF in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of heart failure market diagnosed incident and diagnosed prevalent cases segmented by age and sex. Diagnosed incident cases are further segmented by ejection fraction, ventricular dysfunction, acute HF hospitalizations (by worsening HF, advanced HF, de novo HF), re-admissions (within 3 months) post-discharge after acute HF hospitalization, and hospital length of stay for acute HF hospitalization in these seven markets. Diagnosed prevalent cases are further segmented by chronic HF (by ejection fraction), and also classified according to the New York Heart Association (NYHA) functional classes I-IV, and American College of Cardiology Foundation/American Heart Association (ACCF/AHA) stages B, C and D in these seven markets.
Complete EpiCast and epidemiology forecast report on heart failure market spread across 77 pages, providing 16 data tables and 18 figures supporting HF market analysis is now available with MarketOptimizer.org at http://www.marketoptimizer.org/epicast-report-heart-failure-epidemiology-forecast-to-2025.html .
In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of HF will increase from 1,094,344 cases in 2015 to 1,400,377 cases in 2025 at an Annual Growth Rate (AGR) of 2.80%. In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of chronic HF will increase from 13,756,453 cases in 2015 to 16,105,489 cases in 2025 at an AGR of 1.71%. The US will have the highest number of diagnosed incident cases of HF and diagnosed prevalent cases of chronic HF among the 7MM throughout the forecast period with 1,052,831 diagnosed incident cases of HF and 6,170,142 diagnosed prevalent cases of chronic HF in 2025. In the 7MM in 2015, 37.59% of the diagnosed prevalent cases of chronic HF are in NYHA Class I, 39.54% in NYHA Class II, 19.11% in NYHA Class III, and 3.75% in NYHA Class IV.
Heart Failure (HF), also referred to as congestive cardiac failure, is a heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic needs of the body. Eventually, without the heart's pumping action to deliver oxygen and nutrient-rich blood to the cells, fatigue, shortness of breath, and coughing results. HF commonly occurs in people above 50 years of age, and severity increases progressively with age. Symptoms can develop quickly, such as in acute HF, at which time the patient needs to be hospitalized. However, in chronic HF, the symptoms develop gradually. Due to the chronic nature of cardiovascular diseases, many of the risk factors for HF, such as chronic obstructive pulmonary disease (COPD) and anemia, are also comorbid conditions.
Epidemiologists utilized comprehensive, country-specific data from national HF registers and peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed incident cases of HF, as well as the diagnosed prevalent cases of chronic HF. In this analysis, epidemiologists provide detailed, clinically relevant segmentations for diagnosed incident and diagnosed prevalent cases of HF. Finally, the same forecast methodology was used across the 7MM, thereby allowing for meaningful global comparisons of the diagnosed incident and diagnosed prevalent cases of HF across these markets.
Order a copy of EpiCast Report: Heart Failure - Epidemiology Forecast to 2025 market research at http://www.marketoptimizer.org/contacts/purchase?rname=55738 .
On a related note, another research titled Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, 2016 offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). This report provides top line data relating to the clinical trials on Congestive Heart Failure (Heart Failure). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Read more at http://www.marketoptimizer.org/congestive-heart-failure-heart-failure-global-clinical-trials-review-h1-2016.html .
Explore more reports on the pharmaceuticals market at http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals .
MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Connect with Us: G+ / Google Plus: https://plus.google.com/100862745608219066970 Twitter: https://twitter.com/marketoptimizer Facebook: https://www.facebook.com/MarketOptimizer RSS / Feeds: http://www.marketoptimizer.org/feed
Contact: Ritesh Tiwari UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune - 411013 Maharashtra, India. Tel: +1-888-391-5441 firstname.lastname@example.org
SOURCE Market Optimizer